• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


PROTECT Continuation PAS

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Study Pending
Application Number P200031 / PAS001
Date Current Protocol Accepted  
Study Name PROTECT Continuation PAS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source External Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent A (distinctively) : 18-21 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This study is a continued follow-up of the OCS Liver PROTECT trial (premarket) cohort, designed to evaluate longer-term outcomes after liver transplantation in the OCS and control (cold storage) arms.

Study Population Description Patients who were randomized to OCS or control arms and transplanted in the PROTECT trial

Sample Size 300 patients who were randomized to OCS or control arms and transplanted in the PROTECT trial

Data Collection Main effectiveness endpoint: Liver graft survival at 24 months post-transplant

Other endpoint: patient survival at 24 months post-transplant

Follow-up Visits and Length of Follow-up 2 years

PROTECT Continuation PAS Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
final report 02/28/2022    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources